MEK2(2C3)Mouse Monoclonal Antibody

MEK2(2C3)Mouse Monoclonal Antibody

Size1:50μl Price1:$118
Size2:100μl Price2:$220
Size3:500μl Price3:$980
SKU: AMM13803 Category: Mouse Monoclonal Antibody Tags: , ,

Datasheet

Summary

Production Name

MEK2(2C3)Mouse Monoclonal Antibody

Description

Mouse Monoclonal Antibody

Host

Mouse

Application

WB

Reactivity

Human,Rat,Mouse

 

Performance

Conjugation

Unconjugated

Modification

Unmodified

Isotype

IgG

Clonality

Monoclonal

Form

Liquid

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Buffer

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.

Purification

Affinity purification

 

Immunogen

Gene Name

MAP2K2

Alternative Names

MAP2K2; MEK2; MKK2; PRKMK2; Dual specificity mitogen-activated protein kinase kinase 2; MAP kinase kinase 2; MAPKK 2; ERK activator kinase 2; MAPK/ERK kinase 2; MEK 2

Gene ID

5605

SwissProt ID

P36507

 

Application

Dilution Ratio

WB 1:500-1:2000

Molecular Weight

45kD

 

Background

The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, mental retardation, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. [provided by RefSeq, Jul 2008],catalytic activity:ATP + a protein = ADP + a phosphoprotein.,disease:Defects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.,function:Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases.,PTM:MAPKK is itself dependent on Ser/Thr phosphorylation for activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).,similarity:Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.,similarity:Contains 1 protein kinase domain.,subunit:Interacts with MORG1.,

 

Research Area

MAPK_ERK_Growth;MAPK_G_Protein;ErbB_HER;Vascular smooth muscle contraction;VEGF;Gap junction;Toll_Like;Natural killer cell mediated cytotoxicity;T_Cell_Receptor;B_Cell_Antigen;Fc epsilon RI;Long-term potentiation;Neurotrophin;Long-term depression;Regulates Actin and Cytoskeleton;Insulin_Receptor;GnRH;Melanogenesis;Prion diseases;Pathways in cancer;Renal cell carcinoma;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Non-small cell lung cancer;